As of March 31 the Company had cash, cash equivalents, restricted cash and short-term investments of $121.3M compared to $154.2M as of December 31, 2023. The decrease of $32.9M was primarily driven by $22.6M net cash used in operating activities and $10M for the Beckley Psytech investment. The Company expects its cash, marketable securities and committed term loan facility with Hercules Capital to be sufficient to fund operations into 2026.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- Atai Life Sciences N.V. (ATAI) Q1 Earnings Cheat Sheet
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Atai Life announces dosing of first patient in Phase 2a study of BPL-003
- atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
- Rising High: Exclusive talk with cannabis market research firm BDSA